Key Stats for Novo Nordisk Stock
- Current Price: $45.76
- Target Price (Mid): ~$78
- Street Target: $46.70
- Potential Total Return: ~69%
- Annualized IRR: ~12% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Novo Nordisk (NVO) stock hit a max drawdown of 56.46% on March 30, 2026, one of the steepest declines in the company’s modern history. After back-to-back guidance cuts and the high-profile failure of CagriSema to beat Eli Lilly’s tirzepatide, investors needed proof that the core business could still deliver. Q1 2026 gave them something to work with, but not a clean answer.
Per TIKR’s Beats & Misses data, Q1 2026 total revenue came in at roughly DKK 70.1 billion, missing consensus estimates by 2.09%. Adjusted EPS also missed by 4.75%. What reversed the tone was the Wegovy pill: the pill brought in approximately DKK 2.26 billion in its first full quarter on the U.S. market, against analyst estimates of roughly DKK 1.16 billion compiled by Reuters, nearly double what Wall Street expected. EBITDA beat estimates by 7.62% and net income beat by 11.00%, per TIKR data, though both were partly lifted by a $4.2 billion reversal of a U.S. government drug pricing provision. Novo’s shares rose 6.7% in Copenhagen morning trading before closing about 2.3% higher, with the company lifting its full-year guidance on the back of stronger-than-expected GLP-1 sales.
The Pill Is Opening New Demand
The most important number from Q1 was not on the income statement. EVP of U.S. Operations Jamey Millar disclosed on Novo Nordisk’s investor relations page earnings call that close to 80% of Wegovy pill users are GLP-1 treatment-naive, meaning they had never been on a GLP-1 drug before. That reframes the competitive story. The question for most of 2025 was whether Eli Lilly was taking patients from Novo. The pill appears to be pulling in a different population entirely.
By the week ending April 17, weekly prescriptions reached 207,000. Cumulative scripts since launch exceeded 2 million. All three of the largest pharmacy benefit managers had added the pill to their standard formularies at parity with the injectable version by the end of Q1, setting up a gradual shift from self-pay toward reimbursed coverage. The Wegovy brand now holds around 65% of new-to-brand prescription share in the U.S. obesity market, per Millar on the call.
Eli Lilly launched its competing oral obesity pill, Foundayo, in April. Novo released an indirect treatment comparison, not a head-to-head clinical trial, showing Wegovy produced greater average weight loss and better tolerability. CEO Maziar Doustdar said sales of the pill were growing by double digits despite Lilly’s entry. “The numbers with the pill speak for themselves,” Doustdar told CNBC after the results.
See historical and forward estimates for Novo Nordisk stock (It’s free!) >>>
The Headwinds Have Not Gone Away
The structural pressures that drove NVO’s 56.46% drawdown are still present. On an adjusted basis, excluding the $4.2 billion reversal of a provision tied to the U.S. 340B drug pricing program, adjusted sales declined 4% at constant exchange rates. CFO Karsten Knudsen confirmed on the call that Ozempic U.S. pricing is still eroding at 10% to 15% annually, the same trajectory as 2025.
The full-year guidance improvement was a one-percentage-point parallel shift, not a structural upgrade: adjusted sales are now expected to decline 4% to 12% at constant exchange rates, versus the prior range of 5% to 13%. Analysts at Jefferies said the guidance change was unlikely to have a positive impact on consensus forecasts, with the unchanged lower bound likely to be read as a negative by the market.
Novo has also agreed to Most-Favored-Nation drug pricing with the Trump administration, covering semaglutide agents through the TrumpRx government platform, and for Medicaid beneficiaries. Knudsen acknowledged that the agreement carries a real impact on realized prices going forward.
Per TIKR data, NVO trades at an NTM EV/EBITDA of 10.11x and an NTM P/E of 13.55x. On the TIKR Competitors page, Eli Lilly sits at 21.20x NTM EV/EBITDA and 26.68x NTM P/E. Roche trades at 10.79x and Novartis at 13.47x. Novo’s discount to Lilly is the widest it has been in years, reflecting the market’s view that Lilly is winning on pipeline confidence while Novo bets on volume. That bet is not resolved in one quarter.
See how Novo Nordisk performs against its peers in TIKR (It’s free!) >>>
One Pipeline Win Worth Noting
CSO Martin Lange shared a meaningful update on the call beyond the GLP-1 story. Etavopivat, Novo’s oral treatment for sickle cell disease, an inherited blood disorder that causes abnormally shaped red blood cells, blocked vessels, and severe pain, met both co-primary endpoints in the Phase 3 HIBISCUS trial. It reduced painful vaso-occlusive crises by 27% versus placebo and drove a hemoglobin response in 48.7% of patients compared to 7.2% with placebo. Novo plans to file for U.S. regulatory approval in Q4 2026.
It is one data point. But it supports Doustdar’s stated goal of building “multiple legs” for long-term growth beyond the GLP-1 franchise.
TIKR Advanced Model Analysis
- Current Price: $45.76
- Target Price (Mid): ~$78
- Potential Total Return: ~69%
- Annualized IRR: ~12% / year
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
The TIKR mid-case model targets approximately $78 for NVO by December 31, 2030, implying around 69% total return at an annualized IRR of around 12%. The two primary revenue CAGR drivers in the mid case are global oral Wegovy scaling and an eventual CagriSema contribution following a potential 2027 launch, supporting a mid-case revenue CAGR of around 6%. The margin driver is operating leverage as reimbursed volume grows: the mid case assumes a net income margin of around 34%.
The upside scenario is a successful international Wegovy pill rollout. Novo confirmed a second-half 2026 launch in select markets, pending regulatory decisions. The downside risk is pricing deterioration beyond what management has guided the MFN agreement, Medicaid coverage shifts, and semaglutide patent expiries in select international markets each apply independent pressure. The free cash flow base remains substantial at DKK 119,102 million in LTM operating cash flow as of 12/31/25, per TIKR, but if the pricing trough is deeper than modeled, margin recovery is delayed.
The Street’s current consensus of 4 Buys, 1 Outperform, 9 Holds, and 1 Sell, per TIKR data as of May 6, with a mean target of $46.70, signals limited near-term upside in Wall Street’s view. The TIKR mid-case sees substantially more value over a four-year horizon, but it requires execution that Novo has not yet fully demonstrated.
Conclusion
Watch the Q2 2026 report on August 5. The metric that matters is oral Wegovy retention at the 9mg and 25mg titration doses, which translate directly into revenue per patient as the reimbursed mix grows. If weekly TRxs hold above 200,000 while the channel mix improves, the volume-over-price thesis starts to look credible. Novo posted its strongest product launch on record this quarter, but one quarter does not fix a multi-year reset.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Novo Nordisk?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Novo Nordisk, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Novo Nordisk alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Novo Nordisk on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
